Novorapid Pumpcart (Insulin Aspart)

Insulin aspart, the active ingredient in Novorapid Pumpcart, is a rapid‑acting insulin analog presented as a solution for subcutaneous use. It lowers blood glucose in people with diabetes mellitus. GNH USA supplies Novorapid Pumpcart as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Novorapid Pumpcart as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Novorapid Pumpcart is a rapid‑acting insulin analog that controls post‑prandial glucose excursions in diabetes mellitus.

- Type 1 Diabetes Mellitus: Improves glycaemic control by replacing deficient basal insulin. - Type 2 Diabetes Mellitus: Provides mealtime insulin to manage post‑meal glucose spikes. - Gestational Diabetes Mellitus: Controls post‑prandial glucose levels when diet alone is insufficient.

Insulin aspart may elicit a range of adverse reactions.

Common Side Effects: - Hypoglycaemia:    - Lipodystrophy at injection site. - Local redness   - Itching  - Swelling  - Mild rash 

Serious or Rare Side Effects: - Anaphylaxis   - Severe hypoglycaemia with neurological   -